In the US, I agree. There will be no US approval in 2026, 2027, and 2028. Who knows after that?
In the UK, they may get approval with some caveat, but certainly nothing in 2025. It may happen in 2026. Reimbursement support unlikely in 2026! So 2026 will be another lost year in terms of revenue. No wonder they are trying to explore compassionate use in the US, so they can at least report some modest revenue in 2026. Maybe $5M or so? Or is that too much given how disappointing their Specials program has been!?
It’s likely that by end of 2026, we are over 2.5B shares fully diluted.
Market Data 
Markets 
